The study focuses on preventing a type of diabetes that can appear after a kidney transplantation. This condition, called Post-transplantation Diabetes Mellitus, can develop when the body’s ability to control blood sugar is affected by the transplant and the medicines used. The treatment being tested is a medication that imitates a natural hormone called GLP‑1; the drug’s active ingredient is semaglutide and it is given as a small injection under the skin. This type of drug is known as a GLP‑1RA.
The purpose of the study is to see whether a three‑month course of the medication can keep the diabetes from developing in the first six months after the transplant. Participants who have received a kidney transplant within the past six months will receive the study medication (or a placebo) for three months and will attend regular clinic visits where blood samples are taken. These samples are used to check blood‑sugar control with a test called HbA1c (which shows average sugar levels over several weeks) and to assess kidney function with eGFR (a number that tells how well the kidneys are filtering blood). Other routine checks include weight, blood pressure and simple questionnaires about health.
During the follow‑up period, researchers will also look at other health indicators such as urine protein, cholesterol levels and any signs of organ rejection. In one center, a detailed test called a hyperglycaemic clamp may be performed, using a hormone called glucagon to see how well the pancreas can produce insulin when blood sugar is high. Participants will complete quality‑of‑life surveys to report how they feel overall and whether they experience any stomach symptoms.
The Netherlands 
